LAVA Therapeutics BV (LVTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
LVTX POWR Grades
- LVTX scores best on the Sentiment dimension, with a Sentiment rank ahead of 99.42% of US stocks.
- LVTX's strongest trending metric is Value; it's been moving up over the last 65 days.
- LVTX's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).
LVTX Stock Summary
- With a one year PEG ratio of 0.42, LAVA THERAPEUTICS NV is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.99% of US stocks.
- LAVA THERAPEUTICS NV's stock had its IPO on March 25, 2021, making it an older stock than only 6.81% of US equities in our set.
- Revenue growth over the past 12 months for LAVA THERAPEUTICS NV comes in at 233.3%, a number that bests 96.74% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to LAVA THERAPEUTICS NV, a group of peers worth examining would be GSIT, EIGR, FIXX, OGEN, and HOWL.
- To dig deeper into the stock's financial statements, go to LVTX's page on browse-edgar?action=getcompany&CIK=0001840748.
LVTX Price Target
For more insight on analysts targets of LVTX, see our LVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $23.00 | Average Broker Recommendation | 1.12 (Strong Buy) |
LVTX Stock Price Chart Interactive Chart >
LVTX Price/Volume Stats
| Current price | $1.67 | 52-week high | $7.38 |
| Prev. close | $1.64 | 52-week low | $1.56 |
| Day low | $1.60 | Volume | 27,300 |
| Day high | $1.67 | Avg. volume | 58,795 |
| 50-day MA | $2.62 | Dividend yield | N/A |
| 200-day MA | $3.35 | Market Cap | 42.33M |
LAVA Therapeutics BV (LVTX) Company Bio
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates
Latest LVTX News From Around the Web
Below are the latest news stories about LAVA THERAPEUTICS NV that investors may wish to consider to help them evaluate LVTX as an investment opportunity.
LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsUTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph |
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumFavorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicitiesPreliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in 8 out of 14 evaluable patients at week 8 and PSA levels stabilizing or decreasing in heavily pre-treated patients Dose escalation is ongoing UTRECHT, The Netherlands and PHILADELPHIA, Feb. 16, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-o |
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceUTRECHT, The Netherlands and PHILADELPHIA, Feb. 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present at the 2023 SVB Securities Global Biopharma Conference. Presentation DetailsFormat: Presentation |
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical OfficerUTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. “During a 25-year tenure in the industry, Dr. Morris has dem |
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumUTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 1/2a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Geni |
LVTX Price Returns
| 1-mo | -25.11% |
| 3-mo | -52.29% |
| 6-mo | -63.46% |
| 1-year | -62.05% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -52.29% |
| 2022 | -36.36% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...